{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027190","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.448033+00:00","generated_at":"2026-06-22T23:53:25.616956+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aquestive licenses Sympazan to Assertio for $9M upfront; up to $6M milestone","bullets":["Exclusive worldwide license of Sympazan (clobazam) oral film to Otter Pharmaceuticals (Assertio) for LGS.","Aquestive receives $9M upfront and will get $6M milestone upon patent allowance (notice already received Oct 27, 2022).","Aquestive will also receive royalties from Assertio and serve as exclusive manufacturer under long-term supply agreement.","Deal provides non-dilutive financing to focus on development of AQST-109 (epinephrine sublingual film) for anaphylaxis."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027190","json":"https://secwatch.observer/filing/0001628280-22-027190.json","markdown":"https://secwatch.observer/filing/0001628280-22-027190.md","text":"https://secwatch.observer/filing/0001628280-22-027190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/0001628280-22-027190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/aqst-20221026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:53:25.616956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf24ea8cd8add9a6d49f247a3d63115ac48454bd","claim":"Aquestive Therapeutics, Inc. entered into Assertio License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. valued at $9.0 million (effective 2022-10-26).","evidence_excerpt":"Effective October 26, 2022, Aquestive Therapeutics, Inc. (\"Aquestive\" or the “Company”) entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio”), a specialty pharmaceutical company offering differentiated products to patients, to license Sympazan® (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox‐Gastaut syndrome (LGS) in patients aged two years of age or older (the \"Assertio License Agreement\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/0001628280-22-027190-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc."},{"label":"Value","value":"$9.0 million"},{"label":"Effective","value":"2022-10-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}